ArticleMolecular biology reports2026
Trans-vaccenic acid reduces HT-29 colorectal cancer cell viability and is associated with changes in apoptosis-, lipid metabolism-, and survival-related gene and candidate miRNA expression.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) remains a major cause of cancer-related mortality worldwide, necessitating the identification of novel bioactive compounds with therapeutic potential. Trans-vaccenic acid (TVA), a primary ruminant-derived trans fatty acid, possesses diverse biological activities; however, its cellular effects in CRC and its association with miRNA expression and downstream targets remain to be fully characterized.
methodsIn this study, HT-29 human CRC cells were exposed to increasing concentrations of TVA (0-800 µM). Cell viability was evaluated using the MTT assay, and apoptotic cell populations were quantified using Annexin V-FITC/PI flow cytometry alongside Hoechst 33,342 nuclear staining. The expression levels of apoptosis-, lipid metabolism-, and cell survival-related genes (BAX, CASP3, CASP8, CASP9, MCL1, BCL2, SCD1, and GPR34), as well as candidate miRNAs predicted via miRWalk 2.0, miRDB, and TargetScan, were analyzed by RT-qPCR and ELISA.
resultsTVA reduced HT-29 cell viability in a dose-dependent manner, with an IC₅₀ value of 251.13 µM at 24 h. Hoechst staining revealed apoptotic nuclear changes and apoptotic body formation, while Annexin V-FITC/PI flow cytometry confirmed a predominant increase in late apoptotic cells (p < 0.001). At the molecular level, TVA treatment significantly increased the expression of pro-apoptotic markers (BAX, CASP3, CASP8, and CASP9) and reduced anti-apoptotic (MCL1, BCL2), lipid homeostasis/tumor survival (SCD1), and oncogenic survival signaling (GPR34) markers (p < 0.05). Concurrently, TVA administration was associated with increased expression of candidate miRNAs (let-7e-5p, let-7b-5p, miR-519d-3p, miR-582-5p, and miR-381-3p; p < 0.05), accompanied by changes in the expression of their predicted target transcripts.
conclusionTVA exerts cytotoxic and pro-apoptotic effects in HT-29 cells, accompanied by favorable shifts in lipid metabolism/survival gene expression and candidate miRNA profiles. While these correlative findings support the bioactive potential of TVA in CRC, further studies incorporating multiple cell lines and functional miRNA validation (e.g., mimic/inhibitor transfections) are required to establish direct mechanistic causality.
Indexed as
Identifiers
42886393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.